№ lp_1_2_14476
File format: docx Character count: 58770 File size: 429 KB
Peer-reviewed public health review published in a national surveillance journal examining epidemiology, vaccine performance, safety considerations, and policy implications of herpes zoster vaccination in Australia under the National Immunisation Program.
Year: 2023
Publication date: 27 April 2023
Update date: 3 May 2023
Journal: Communicable Diseases Intelligence
Volume: 47
DOI: 10.33321/cdi.2023.47.21
Country: Australia
Authors: Yuanfei Anny Huang; Jean Li-Kim-Moy; Sanjay Jayasinghe; Clayton Chiu; Kristine Macartney; Bette Liu; Penelope Burns; Michelle Giles; Nigel Crawford on behalf of ATAGI
Organisation: Australian Technical Advisory Group on Immunisation
Topic: Herpes zoster vaccination
Vaccines discussed: Zostavax (ZVL); Shingrix (RZV)
Immunisation program: Australian National Immunisation Program
Target population: Older adults; immunocompromised people
Document type: Targeted review
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Patient Group Direction for treatment of Herpes Zoster (Shingles) in patients aged 18 years and over
Note: Year
Theme: Herpes Zoster (Shingles) Treatment
Document Type: Patient Group Direction
Organization / Institution: NHS Pharmacy First Scotland
Target Audience: Healthcare professionals (pharmacists, GPs)
Herpes Viruses – Lecture 6: Classification, Morphology, Pathogenesis and Laboratory Diagnosis
Year: Not specified
Region / Country: Not specified
Academic Field: Virology
Topic: Human herpes viruses and associated diseases
Document Type: Lecture notes
Institution / Organization: Not specified
Author: Not specified
Target Audience: Medical or microbiology students
Viruses Discussed: Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human herpesvirus 8 (HHV-8)
Subfamilies: Alpha Herpesvirinae, Beta Herpesvirinae, Gamma Herpesvirinae
Genome Type: Double-stranded DNA (dsDNA)
Virion Structure: Core, Capsid, Tegument, Envelope
Transmission Routes: Direct contact, respiratory droplets, sexual transmission, perinatal transmission
Diseases Mentioned: Herpes simplex infection, Varicella (chickenpox), Herpes zoster (shingles)
Diagnostic Methods: Giemsa staining, electron microscopy, immunofluorescence, PCR, virus isolation, serology (ELISA, IF)
Key Biological Feature: Lifelong latency with periodic reactivation
VARICELLA ZOSTER VIRUS RECOMBINANT VACCINE, Injection [1 vial] & adjuvant substance diluent [0.5 mL vial], Shingrix®, GlaxoSmithKline Australia Pty Ltd
Year: 2023
Region / city: Australia
Topic: Vaccination, Immunocompromised individuals, Herpes Zoster
Document type: Government recommendation
Organization: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: PBAC
Target audience: Healthcare professionals, Immunocompromised individuals
Period of validity: From November 1, 2023
Approval date: November 1, 2023
Modification date: September 2023
Patient Group Direction for treatment of Herpes Zoster (Shingles) in patients aged 18 years and over
Note: Year
Theme: Herpes Zoster (Shingles) Treatment
Document Type: Patient Group Direction
Organization / Institution: NHS Pharmacy First Scotland
Target Audience: Healthcare professionals (pharmacists, GPs)
Australia’s national zoster vaccination program: Knowledge, attitudes and behaviour of general practitioners
Authors: Harunor Rashid; Aditi Dey; Ramesh Manocha; Mohamed Tashani; Kristine Macartney; Frank Beard
Year: 2017
Country: Australia
Topic: Herpes zoster vaccination; general practitioner knowledge and practice; National Immunisation Program
Document type: Peer-reviewed research article
Study design: National cross-sectional online survey
Study period: 16 October – 3 November 2017
Population: Australian general practitioners
Sample size: 1026 respondents
Program reference: National Immunisation Program (from 1 November 2016)
Vaccine discussed: Zostavax® (live attenuated zoster vaccine); Shingrix® (recombinant subunit vaccine)
Target age group: Adults aged 70–79 years (NIP-funded); adults aged ≥60 years (recommended)
Ethics approval: Sydney Children’s Hospitals Network Human Research Ethics Committee (Ref: LNR/17/SCHN/250)
Data collection tool: Web-based questionnaire (SurveyMonkey®)
Keywords: general practitioner; herpes zoster; immunocompromise; post-herpetic neuralgia; zoster vaccine
Topics: ATAGI herpes zoster